NASDAQ:AMED Amedisys (AMED) Stock Price, News & Analysis → Central Bank Gold Heist In Progress (From Colonial Metals) (Ad) Free AMED Stock Alerts $93.44 +0.23 (+0.25%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$92.87▼$93.7150-Day Range$92.78▼$95.2452-Week Range$69.36▼$96.44Volume284,533 shsAverage Volume291,431 shsMarket Capitalization$3.05 billionP/E RatioN/ADividend YieldN/APrice Target$97.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Amedisys alerts: Email Address Amedisys MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside3.8% Upside$97.00 Price TargetShort InterestBearish9.83% of Float Sold ShortDividend StrengthN/ASustainability-0.61Upright™ Environmental ScoreNews Sentiment1.10Based on 5 Articles This WeekInsider TradingN/AProj. Earnings Growth9.03%From $4.54 to $4.95 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.65 out of 5 starsMedical Sector497th out of 947 stocksHome Health Care Services Industry6th out of 8 stocks 1.0 Analyst's Opinion Consensus RatingAmedisys has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 6 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $97.00, Amedisys has a forecasted upside of 3.8% from its current price of $93.44.Amount of Analyst CoverageAmedisys has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.83% of the float of Amedisys has been sold short.Short Interest Ratio / Days to CoverAmedisys has a short interest ratio ("days to cover") of 9.7.Change versus previous monthShort interest in Amedisys has recently increased by 4.33%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAmedisys does not currently pay a dividend.Dividend GrowthAmedisys does not have a long track record of dividend growth. Previous Next 5.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAmedisys has received a 82.47% net impact score from Upright. Amedisys seems to create the most significant positive value in categories "Jobs", "Meaning & joy", and "Taxes". The positive contribution in the "Meaning & joy" impact category is mostly driven by its "Private hospice care", "Private speech therapy services", and "Private occupational physiotherapy services" products. See details.Environmental SustainabilityThe Environmental Impact score for Amedisys is -0.61. Previous Next 3.4 News and Social Media Coverage News SentimentAmedisys has a news sentiment score of 1.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Amedisys this week, compared to 3 articles on an average week.MarketBeat Follows2 people have added Amedisys to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amedisys insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.80% of the stock of Amedisys is held by insiders.Percentage Held by Institutions95.70% of the stock of Amedisys is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Amedisys are expected to grow by 9.03% in the coming year, from $4.54 to $4.95 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amedisys is -301.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amedisys is -301.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioAmedisys has a PEG Ratio of 2.08. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAmedisys has a P/B Ratio of 2.72. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Prosper Trading AcademyDid you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:Click Here To Get Your Free Copy About Amedisys Stock (NASDAQ:AMED)Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care, and palliative care to patients in their homes. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.Read More AMED Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AMED Stock News HeadlinesMarch 15, 2024 | americanbankingnews.comAmedisys, Inc. (NASDAQ:AMED) Given Average Rating of "Hold" by BrokeragesMarch 15, 2024 | americanbankingnews.comStockNews.com Begins Coverage on Amedisys (NASDAQ:AMED)March 19, 2024 | Colonial Metals (Ad)Central Bank Gold Heist In ProgressWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.February 24, 2024 | finance.yahoo.comCAH Mar 2024 103.000 putFebruary 23, 2024 | finanznachrichten.deAmedisys, Inc.: Amedisys Reports Fourth Quarter and Year-End 2023 Financial ResultsFebruary 23, 2024 | uk.finance.yahoo.comQ4 2023 Blue Owl Capital Corp Earnings CallFebruary 22, 2024 | finance.yahoo.comAmedisys (AMED) Reports Q4 Earnings: What Key Metrics Have to SayFebruary 21, 2024 | msn.comAmedisys (AMED) Q4 Earnings Lag EstimatesMarch 19, 2024 | InvestorPlace (Ad)They said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.February 21, 2024 | finance.yahoo.comAmedisys Reports Fourth Quarter and Year-End 2023 Financial ResultsFebruary 21, 2024 | finance.yahoo.comAmedisys Inc (AMED) Reports Mixed Results Amidst Merger TransactionsFebruary 21, 2024 | globenewswire.comAmedisys Reports Fourth Quarter and Year-End 2023 Financial ResultsFebruary 21, 2024 | finance.yahoo.comKain Capital-Backed PERA Holdings Hires CEO and CCOFebruary 18, 2024 | finance.yahoo.comAMED Mar 2024 95.000 putFebruary 17, 2024 | finance.yahoo.comAMED Mar 2024 70.000 putFebruary 16, 2024 | finance.yahoo.comAMED Feb 2024 90.000 callFebruary 15, 2024 | msn.comStocks See Support as Weak Retail Sales Report Bolsters Fed Rate-Cut HopesFebruary 14, 2024 | msn.comCentene (CNC) to Provide Better Health Equity in North CarolinaFebruary 14, 2024 | finance.yahoo.comAmedisys (AMED) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 ReleaseFebruary 8, 2024 | finanznachrichten.deAmedisys, Inc.: Amedisys Offers Molecular Testing for Rapid and Accurate Infection DiagnosisFebruary 8, 2024 | finance.yahoo.comAmedisys Offers Molecular Testing for Rapid and Accurate Infection DiagnosisFebruary 6, 2024 | finanznachrichten.deHome Healthcare Market Worth $383.0 Billion | MarketsandMarkets.January 22, 2024 | startribune.comApple Valley's Uponor hopes new owner will accelerate its Mexico, South America growthJanuary 12, 2024 | msn.comEnergy Prices Are Falling, and the Stocks Are Out of Favor. That’s the Good News.January 9, 2024 | usnews.comBest Pregnancy Pillows of 2024January 3, 2024 | axios.comScoop: Infusion Associates coming to marketJanuary 3, 2024 | msn.comUPDATE 2-KKR-backed BrightSpring revives US IPO planSee More Headlines Receive AMED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amedisys and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/21/2024Today3/18/2024Next Earnings (Estimated)5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Home health care services Sub-IndustryHealth Care Services Current SymbolNASDAQ:AMED CUSIP02343610 CIK896262 Webwww.amedisys.com Phone(225) 292-2031Fax225-292-8163Employees19,000Year Founded1982Price Target and Rating Average Stock Price Target$97.00 High Stock Price Target$101.00 Low Stock Price Target$81.00 Potential Upside/Downside+3.8%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.31) Trailing P/E RatioN/A Forward P/E Ratio20.58 P/E Growth2.08Net Income$-9,750,000.00 Net Margins-0.44% Pretax Margin1.77% Return on Equity12.76% Return on Assets7.02% Debt Debt-to-Equity Ratio0.32 Current Ratio1.05 Quick Ratio1.05 Sales & Book Value Annual Sales$2.24 billion Price / Sales1.37 Cash Flow$6.16 per share Price / Cash Flow15.18 Book Value$34.31 per share Price / Book2.72Miscellaneous Outstanding Shares32,670,000Free Float32,080,000Market Cap$3.05 billion OptionableOptionable Beta0.86 Social Links 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Scott G. Ginn (Age 55)Executive VP, COO, CFO & Principal Financial Officer Comp: $659.94kMr. Michael P. North (Age 59)Chief Information Officer Comp: $442.38kMs. Denise Bohnert (Age 46)Chief Compliance Officer Comp: $399.72kMr. Nick Muscato (Age 38)Chief Strategy Officer Comp: $400.94kMr. Richard M. Ashworth (Age 49)President, CEO & Director Ms. Allyson GuidrozChief Accounting Officer & Principal Accounting OfficerMr. Pete HartleyCTO & Senior VP of Business Operations SystemsMs. Jennifer Guckert GriffinSenior VP, Deputy General Counsel, Corporate Secretary & Interim Chief Legal OfficerKendra KimmonsVP of Marketing & Communications & Media RelationsMr. Adam Holton (Age 53)Chief People Officer More ExecutivesKey CompetitorsLHC GroupNASDAQ:LHCGChemedNYSE:CHEAddus HomeCareNASDAQ:ADUSBrightSpring Health ServicesNASDAQ:BTSGAdaptHealthNASDAQ:AHCOView All CompetitorsInstitutional OwnershipVanguard Group Inc.Sold 22,568 shares on 3/11/2024Ownership: 9.852%Goldman Sachs Group Inc.Bought 81,031 shares on 3/1/2024Ownership: 0.412%American International Group Inc.Sold 1,897 shares on 2/28/2024Ownership: 0.135%FIL LtdBought 1,305,333 shares on 2/17/2024Ownership: 4.000%Public Employees Retirement System of OhioBought 371 shares on 2/16/2024Ownership: 0.070%View All Institutional Transactions AMED Stock Analysis - Frequently Asked Questions Should I buy or sell Amedisys stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last twelve months. There are currently 6 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" AMED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMED, but not buy additional shares or sell existing shares. View AMED analyst ratings or view top-rated stocks. What is Amedisys' stock price target for 2024? 6 analysts have issued 1 year price targets for Amedisys' stock. Their AMED share price targets range from $81.00 to $101.00. On average, they expect the company's share price to reach $97.00 in the next year. This suggests a possible upside of 3.8% from the stock's current price. View analysts price targets for AMED or view top-rated stocks among Wall Street analysts. How have AMED shares performed in 2024? Amedisys' stock was trading at $95.06 at the beginning of 2024. Since then, AMED shares have decreased by 1.7% and is now trading at $93.44. View the best growth stocks for 2024 here. When is Amedisys' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our AMED earnings forecast. How were Amedisys' earnings last quarter? Amedisys, Inc. (NASDAQ:AMED) released its earnings results on Wednesday, February, 21st. The health services provider reported $0.94 EPS for the quarter, missing the consensus estimate of $1.04 by $0.10. The health services provider earned $570.79 million during the quarter, compared to analysts' expectations of $566.85 million. Amedisys had a positive trailing twelve-month return on equity of 12.76% and a negative net margin of 0.44%. The company's revenue was up 1.6% compared to the same quarter last year. During the same period in the previous year, the company earned $1.16 earnings per share. What ETFs hold Amedisys' stock? ETFs with the largest weight of Amedisys (NASDAQ:AMED) stock in their portfolio include First Trust Merger Arbitrage ETF (MARB), SRH U.S. Quality ETF (SRHQ), SPDR S&P Health Care Services ETF (XHS) and IQ Merger Arbitrage ETF (MNA).iShares U.S. Healthcare Providers ETF (IHF). What is Paul B. Kusserow's approval rating as Amedisys' CEO? 478 employees have rated Amedisys Chief Executive Officer Paul B. Kusserow on Glassdoor.com. Paul B. Kusserow has an approval rating of 79% among the company's employees. 60.0% of employees surveyed would recommend working at Amedisys to a friend. What other stocks do shareholders of Amedisys own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Adobe (ADBE), Intel (INTC), QUALCOMM (QCOM), Broadcom (AVGO), Cisco Systems (CSCO) and Home Depot (HD). Who are Amedisys' major shareholders? Amedisys' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.86%), Vanguard Group Inc. (9.85%), FIL Ltd (4.00%), Alpine Associates Management Inc. (3.90%), Westchester Capital Management LLC (2.70%) and Mackenzie Financial Corp (2.69%). Insiders that own company stock include Bruce D Perkins, Christopher Gerard, David L Kemmerly, David L Kemmerly, Denise M Bohnert, Michael Paul North, Richard A Lechleiter and Scott G Ginn. View institutional ownership trends. How do I buy shares of Amedisys? Shares of AMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AMED) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressAltcoin FRENZY Alert…Crypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportThe world’s greatest investmentPorter & CompanyMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amedisys, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.